Ionis Pharmaceuticals (IONS) Total Debt (2009 - 2026)

Ionis Pharmaceuticals' Total Debt history runs 18 years deep, the most recent figure standing at $432.5 million for Q1 2026.

• In Q1 2026, Total Debt changed N/A year-over-year to $432.5 million; the TTM figure through Mar 2026 stood at $432.5 million (changed N/A YoY), while the FY2025 annual figure was $460.1 million, up 786.04% from the prior year.
• Total Debt was $432.5 million for Q1 2026 at Ionis Pharmaceuticals, down from $460.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $630.9 million in Q3 2025 to a low of $8.8 million in Q1 2023.
• Historically, Total Debt has averaged $186.2 million across 5 years, with a median of $57.8 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Total Debt slumped 86.16% in 2023, then surged 1318.83% in 2025.
• A 5-year view of Total Debt shows it stood at $16.0 million in 2022, then soared by 439.46% to $86.2 million in 2023, then tumbled by 39.74% to $51.9 million in 2024, then jumped by 786.04% to $460.1 million in 2025, then declined by 5.99% to $432.5 million in 2026.
• The last three Total Debt figures came in at $432.5 million (Q1 2026), $460.1 million (Q4 2025), and $630.9 million (Q3 2025), per Business Quant data.